MIRA INFORM REPORT

 

 

Report Date :

16.12.2013

 

IDENTIFICATION DETAILS

 

Name :

COOPER PHARMA

 

 

Formerly Known As :

COOPER MAROC

 

 

Registered Office :

41 Rue Mohamed Diouri, Casablanca, BP 13278 – 20110, Casablanca

 

 

Country :

Morocco

 

 

Date of Incorporation :

11.05.1933

 

 

Com. Reg. No.:

RC29615

 

 

Legal Form :

Limited Corporation 

 

 

Line of Business :

Manufacturer and supply of pharmaceutical products and related facilities

 

 

No. of Employees :

930

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No complaints

 

 

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March, 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Morocco

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

MOROCCO - ECONOMIC OVERVIEW

 

Morocco has capitalized on its proximity to Europe and relatively low labor costs to build a diverse, open, market-oriented economy. In the 1980s Morocco was a heavily indebted country before pursuing austerity measures and pro-market reforms, overseen by the IMF. Since taking the throne in 1999, King MOHAMMED VI has presided over a stable economy marked by steady growth, low inflation, and gradually falling unemployment, although a poor harvest and economic difficulties in Europe contributed to an economic slowdown in 2012. Industrial development strategies and infrastructure improvements - most visibly illustrated by a new port and free trade zone near Tangier - are improving Morocco's competitiveness. Morocco also seeks to expand its renewable energy capacity with a goal of making renewable 40% of electricity output by 2020. Key sectors of the economy include agriculture, tourism, phosphates, textiles, apparel, and subcomponents. To boost exports, Morocco entered into a bilateral Free Trade Agreement with the United States in 2006 and an Advanced Status agreement with the European Union in 2008. Despite Morocco's economic progress, the country suffers from high unemployment, poverty, and illiteracy, particularly in rural areas. In 2011 and 2012, high prices on fuel - which is subsidized and almost entirely imported - strained the government''s budget and widened the country''s current account deficit. Key economic challenges for Morocco include fighting corruption and reforming the education system, the judiciary, and the government''s costly subsidy program.

 

Source : CIA

 

SUBJECT'S NAME

 

Registered Name:

COOPER PHARMA

Requested Name:

COOPER PHARMA

Former Names:

COOPER MAROC

 

 

ADDRESS AND TELECOMMUNICATION

 

Physical Address:

41 Rue Mohamed Diouri, Casablanca,

Postal Address:

BP 13278 – 20110,

 

Casablanca,

Country:

Morocco

Phone:

212-522453200 / 331352

Fax:

212-522304853 / 331337

Email:

info@cooperpharma.ma

Website:

www.cooperpharma.ma

 

 

LEGAL

 

Legal Form:

Limited Corporation 

Date Incorporated:

11-May-1933

Reg. Number:

RC29615

Nominal Capital

MAD. 264,000,000

Subscribed Capital

MAD. 264,000,000

Subscribed Capital is Subscribed in the following form:

 

Position

Shares

Mr. Jaouad Cheikh Lahlou

Chairman

 

Mr. Ayman Cheikh Lahlou

Director

 

Akzo Nobel

Shareholder

17%

Private Investors

Shareholder

83%

 

 

RELATED COMPANIES

 

Cooper Melun (France)

Parent company.

Cooper Sophadet : Tanger,

Cooper Cophag : Agadir,

Cooper Oriental Medica : Oujda,

Cooper Groupement Pharmaceutique : Fès,

Cooper Chaouia Ouardigha : Khouribga,

Cooper Dismedic : Casablanca,

Cooper Beni Snassen : Berkane.

Subsidiary companies.

None

Affiliated company.

None

Shareholder of subject firm.

Usine : km 2,5, rte 107, douar Ouled Sidi Abbou - Tit Mellil, Morocco

Branches of the firm

 

 

OPERATIONS

 

Registered to operate as manufacturer and supply of pharmaceutical products and related facilties

Imports:

Middle East

Exports:

Europe

Trademarks:

None

Terms of sale:

Cash (40%) and 25-90 days (60%), invoices.

 

 

Main Customers:

firms and organizations  

Employees:

930 employees.

Vehicles:

Several motor vehicles.

Territory of sales:

Morocco

Location:

Owned premises, 10,000 square feet,

 

 

AUDITORS AND INSURANCE

 

Auditors:

Information not available.

Insurance Brokers:

Information not available.

 

 

 

 

FINANCE

 

Currency Reported:

Moroccan Dirham (MAD.)

Approx. Ex. Rate:

1 US Dollar = 8.17 Moroccan Dirham

Fiscal Year End:

December 31, 2012

Inflation:

According to information given by independent sources, the inflation at December 31st, 2012 was of 13%.

 

Financial Information not Submitted

 

 

 

 

 

Profit and Loss (expressed in USD.)

 

 

2012

Sales

 

165,400,000

 

BANK

 

Bank Name:

Société Générale Maroc

Branch:

Morocco

Comments:

None

 

 

 

 

TRADE REFERENCES

 

Experiences:

Good

 

 

 

 

NOTARIAL BONDS

 

None

 

 

COMMENTS / ADDITIONAL INFORMATION

 

This information was obtained from outside sources other than the subject company itself and confirmed the above subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.62.13

UK Pound

1

Rs.101.53

Euro

1

Rs.85.41

 

 

INFORMATION DETAILS

 

Report Prepared by :

NNA

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.